Yaral Continues Build With ‘Unique’ Levothyroxine Formulation
Authorized Generic Tirosint Adds To Growing Portfolio; Product Is ‘Specially Formulated’
Executive Summary
After launching at the end of 2022, IBSA’s dedicated US authorized generics and complex generics unit, Yaral Pharma, has brought on board another of its parent company’s products.